GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Cyclically Adjusted PS Ratio

Alnylam Pharmaceuticals (BSP:A1LN34) Cyclically Adjusted PS Ratio : 38.03 (As of Mar. 02, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2025-03-02), Alnylam Pharmaceuticals's current share price is R$71.88. Alnylam Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was R$1.89. Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 38.03.

The historical rank and industry rank for Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:A1LN34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 21.77   Med: 63.85   Max: 121.08
Current: 40.39

During the past years, Alnylam Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 121.08. The lowest was 21.77. And the median was 63.85.

BSP:A1LN34's Cyclically Adjusted PS Ratio is ranked worse than
90.93% of 441 companies
in the Biotechnology industry
Industry Median: 5.76 vs BSP:A1LN34: 40.39

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alnylam Pharmaceuticals's adjusted revenue per share data for the three months ended in Dec. 2024 was R$1.401. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$1.89 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alnylam Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.60 82.44 82.70 44.45 38.52

Alnylam Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.45 31.39 45.88 48.37 38.52

Competitive Comparison of Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Alnylam Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=71.88/1.89
=38.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Alnylam Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=1.401/133.1571*133.1571
=1.401

Current CPI (Dec. 2024) = 133.1571.

Alnylam Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.035 99.621 0.047
201506 0.016 100.684 0.021
201509 0.015 100.392 0.020
201512 0.017 99.792 0.023
201603 0.016 100.470 0.021
201606 0.017 101.688 0.022
201609 0.026 101.861 0.034
201612 0.034 101.863 0.044
201703 0.034 102.862 0.044
201706 0.030 103.349 0.039
201709 0.029 104.136 0.037
201712 0.065 104.011 0.083
201803 0.036 105.290 0.046
201806 0.056 106.317 0.070
201809 0.004 106.507 0.005
201812 0.040 105.998 0.050
201903 0.061 107.251 0.076
201906 0.079 108.070 0.097
201909 0.133 108.329 0.163
201912 0.132 108.420 0.162
202003 0.216 108.902 0.264
202006 0.235 108.767 0.288
202009 0.293 109.815 0.355
202012 0.361 109.897 0.437
202103 0.427 111.754 0.509
202106 0.471 114.631 0.547
202109 0.416 115.734 0.479
202112 0.610 117.630 0.691
202203 0.441 121.301 0.484
202206 0.469 125.017 0.500
202209 0.567 125.227 0.603
202212 0.713 125.222 0.758
202303 0.670 127.348 0.701
202306 0.621 128.729 0.642
202309 1.411 129.860 1.447
202312 0.858 129.419 0.883
202403 0.976 131.776 0.986
202406 1.402 132.554 1.408
202409 1.079 133.029 1.080
202412 1.401 133.157 1.401

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alnylam Pharmaceuticals  (BSP:A1LN34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Alnylam Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals Headlines

No Headlines